Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000249.4 | MANE Select | 2494 nt | 31–2301 |
| NM_000249.3 | RefSeq Select | 2662 nt | 199–2469 |
| NM_000249.2 | Alternative | 2524 nt | 61–2331 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenThis sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 561 of the MLH1 protein (p.Tyr561Cys). This variant is present in population databases (no rsID available, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of MLH1-related conditions (PMID: 10612827, 21520333). ClinVar contains an entry for this variant (Variation ID: 483536). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MLH1 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
"This variant has been reported in ClinVar as Uncertain significance (10 clinical laboratories) and as Uncertain Significance (1 clinical laboratories)."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: MLH1Y561CMLH1Y561CSomaticNCBI Gene:4292|Show additional gene information Variant OverviewMLH1, a DNA mismatch repair protein, is recurrently altered by deletion and mutation in various cancer types.The MLH1 Y561C mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown. JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.0 | 43 bp |
| Donor Loss (DL) | 0.0 | 49 bp |
| Acceptor Gain (AG) | 0.01 | -9 bp |
| Donor Gain (DG) | 0.0 | 436 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP4 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)